Literature DB >> 14714617

Naturally occurring antibodies to epithelial cell adhesion molecule (EpCAM).

Irena Kirman1, Dareema Jenkins, Ryan Fowler, Richard L Whelan.   

Abstract

Epithelial cell adhesion molecule (Ep-CAM) is an epithelial tumor-associated antigen that is expressed by a number of normal tissues and has been used as a target in many immunotherapy studies. The purpose of this study was to determine the incidence of serum anti-EpCAM IgG (immunoglobulin G) antibodies in colon cancer and tumor-free patients and to assess the tumor protective value of anti-EpCAM antibodies. One third of both the cancer (16/48) and the control (9/27) patients had detectable antibodies. Although the mean antibody concentration was higher in cancer patients (0.048 +/- 0.120 U) than in controls (0.038 +/- 0.064 U) the difference was not statistically significant. Western blot analysis revealed reactivity to multiple HT29 cell proteins including a 40-kDa protein (presumed to be Ep-CAM). Monoclonal anti-EpCAM 323/A3 antibody did not have a tumor-protective effect in murine Ep-CAM expressing colocarcinoma. We conclude that Ep-CAM is immunogenic not only for cancer patients, but also for tumor-free individuals.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14714617     DOI: 10.1023/b:ddas.0000007867.25896.ce

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  19 in total

1.  Circulating anti-CEA antibodies in the sera of patients with breast cancer.

Authors:  D Haidopoulos; M M Konstadoulakis; P T Antonakis; D G Alexiou; A M Manouras; S M Katsaragakis; G F Androulakis
Journal:  Eur J Surg Oncol       Date:  2000-12       Impact factor: 4.424

2.  Comparisons between two monoclonal antibodies that bind to the same antigen but have differing affinities: uptake kinetics and 125I-antibody therapy efficacy in multicell spheroids.

Authors:  V K Langmuir; H L Mendonca; D V Woo
Journal:  Cancer Res       Date:  1992-09-01       Impact factor: 12.701

3.  Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial.

Authors:  G Riethmüller; E Holz; G Schlimok; W Schmiegel; R Raab; K Höffken; R Gruber; I Funke; H Pichlmaier; H Hirche; P Buggisch; J Witte; R Pichlmayr
Journal:  J Clin Oncol       Date:  1998-05       Impact factor: 44.544

4.  Autoantibodies against the tumour-associated antigen GA733-2 in patients with colorectal carcinoma.

Authors:  S Mosolits; U Harmenberg; U Rudén; L Ohman; B Nilsson; B Wahren; J Fagerberg; H Mellstedt
Journal:  Cancer Immunol Immunother       Date:  1999-02       Impact factor: 6.968

5.  Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies.

Authors:  M Herlyn; Z Steplewski; D Herlyn; H Koprowski
Journal:  Proc Natl Acad Sci U S A       Date:  1979-03       Impact factor: 11.205

6.  Colorectal cancer vaccines: antiidiotypic antibody, recombinant protein, and viral vector.

Authors:  S Basak; S Eck; R Gutzmer; A J Smith; B Birebent; E Purev; L Staib; R Somasundaram; J Zaloudik; W Li; L Jacob; E Mitchell; D Speicher; D Herlyn
Journal:  Ann N Y Acad Sci       Date:  2000-06       Impact factor: 5.691

Review 7.  The biology of the 17-1A antigen (Ep-CAM).

Authors:  M Balzar; M J Winter; C J de Boer; S V Litvinov
Journal:  J Mol Med (Berl)       Date:  1999-10       Impact factor: 4.599

8.  Prognostic significance of circulating antibodies against carcinoembryonic antigen (anti-CEA) in patients with colon cancer.

Authors:  K Albanopoulos; A Armakolas; M M Konstadoulakis; E Leandros; E Tsiompanou; E Tsiobanou; S Katsaragakis; D Alexiou; G Androulakis
Journal:  Am J Gastroenterol       Date:  2000-04       Impact factor: 10.864

9.  Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study.

Authors:  Cornelis J A Punt; Attila Nagy; Jean-Yves Douillard; Arie Figer; Torben Skovsgaard; John Monson; Carlo Barone; George Fountzilas; Hanno Riess; Eugene Moylan; Delyth Jones; Juergen Dethling; Jessica Colman; Lorna Coward; Stuart MacGregor
Journal:  Lancet       Date:  2002-08-31       Impact factor: 79.321

10.  Serum antibodies against p53 in relation to cancer risk and prognosis in breast cancer: a population-based epidemiological study.

Authors:  P Lenner; F Wiklund; S O Emdin; C Arnerlöv; C Eklund; G Hallmans; H Zentgraf; J Dillner
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

View more
  2 in total

1.  Stage-specific regulation of adhesion molecule expression segregates epithelial stem/progenitor cells in fetal and adult human livers.

Authors:  Mari Inada; Daniel Benten; Kang Cheng; Brigid Joseph; Ekaterine Berishvili; Sunil Badve; Lennart Logdberg; Mariana Dabeva; Sanjeev Gupta
Journal:  Hepatol Int       Date:  2007-11-27       Impact factor: 6.047

2.  Immune responses in advanced colorectal cancer following repeated intradermal vaccination with the anti-CEA murine monoclonal antibody, PR1A3: results of a phase I study.

Authors:  A P Zbar; H Thomas; R W Wilkinson; M Wadhwa; K N Syrigos; E L Ross; P Dilger; T G Allen-Mersh; W A Kmiot; A A Epenetos; D Snary; W F Bodmer
Journal:  Int J Colorectal Dis       Date:  2005-04-30       Impact factor: 2.571

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.